New Blood Test to Predict Reaction to Anti-TNF Therapies

Trial Objective

New Blood Test to Predict Reaction to Anti-TNF TherapiesThis study evaluates an investigational blood test called PrismRATM that identifies patients who may not respond well to anti-TNF therapies. By identifying patients who won’t respond to anti-TNF therapies before they start treatment, health care providers will be able to start alternative approved targeted therapies for these patients earlier and, potentially, reach low disease activity (LDA) sooner.

Enrollment

Active Clinical Trials Currently Recruiting

Who Can Participate

Age: 18+    Gender: Any Gender


Estimated Time Commitment

4 clinic visits over 6 months



Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Not Available

Trial Contact

For more information, contact:

Megan Rosa

Megan Rosa
303.270.2615

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Scipher Medicine, Corp.

Principal Investigators

Co-Investigators


Request More Information

After limiting clinical research activity due to safety concerns about COVID-19, we are now restarting clinical research in stages. If you are interested in any of the clinical trials posted on our website, please request trial information. We will respond and share the timing for enrollment resuming. Learn More


*
*
*
*